Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Psychopharmacological studies usually attempt to eliminate "nonspecific" influences on outcome by double-blind designs. In a randomized, double-blind comparison of alprazolam, imipramine, and placebo, the great majority of panic disorder patients (N = 59) and their physicians were able to rate accurately whether active drug or placebo had been given. Moreover, physicians could distinguish between the two types of active drugs. Inasmuch as correct rating was possible halfway through treatment, concerns about the internal validity of the double-blind strategy arise.

Type

Journal article

Journal

J Consult Clin Psychol

Publication Date

02/1991

Volume

59

Pages

184 - 187

Keywords

Adult, Alprazolam, Anxiety Disorders, Double-Blind Method, Female, Humans, Imipramine, Male, Middle Aged, Panic, Placebos, Psychotherapy